Skip to main content

Table 1 Baseline characteristics of the 23 study patients who underwent exenteration

From: Pelvic exenteration in gynecologic cancer: complications and oncological outcome

Presentation of disease [n (%)]

 First diagnosis

2 (9)

 Relapse

19 (82)

 Persistence

2 (9)

Age [Mean ± SD (range)]

57.8  ± 12.4 (29–84)

BMI [Mean ± SD (range)]

27.4  ± 7.1 (17–50)

Menopausal status [n (%)]

 Pre

17 (74)

 Post

6 (26)

ECOG performance status [n (%)]

 0

20 (87)

 1

2 (9)

 2

1 (4)

Comorbidity [n (%)]

 None

15 (65)

 Hypertension

5 (22)

 Diabetes mellitus

5 (22)

 Hypercholesterolemia

1 (4)

 Monorenal

1 (4)

Primary tumour origin [n (%)]

 Vulvar cancer

9 (39)

 Cervix cancer

11 (48)

 Endometrial cancer

3 (13)

Previous treatment [n (%)]

 None

3 (13)

 RT

4 (17)

 ChT

0 (0)

 RT + ChT

16 (70)

Previous oncological surgery [n (%)]

 No

5 (22)

 Yes

18 (78)

ASA score [n (%)]

 1

1 (4)

 2

18 (78)

 3

4 (17)

Operative intention [n (%)]

 Curative

21 (91)

 Palliative

2 (9)

  1. BMI body mass index, ECOG Eastern Cooperative Oncology Group, RT radiotherapy, ChT chemotherapy, ASA operative risk assessed according to the American Society of Anaesthesiology score